Radiology AI Governance Model

Model Design by Kelly Emrick, DHSc, PhD, MBA

How Do I Use the Radiology AI Governance Knowledge Base Model? The interactive model serves as a practical reference for radiology executives and IT leaders managing the governance challenges of clinical AI. Start with the Overview tab to understand the eight governance goals and what makes radiology data uniquely complex. From there, the model can be explored in any sequence: open Stakeholders & RACI when forming an AI committee or defining responsibilities; review the Data Lifecycle tab step-by-step when designing data flows or auditing existing ones; refer to Technical Controls during vendor assessments or when planning privacy-preserving architectures like federated learning or secure enclaves. The Bias, Quality & Drift, and Model Governance tabs support the clinical safety discussion, while the Regulatory Compass consolidates your obligations under HIPAA, GDPR, FDA SaMD, and the EU AI Act into one view. The model concludes with the Maturity Assessment, a 42-item self-evaluation covering seven domains that generates a live radar chart, an overall maturity level (from Initial to Optimized), and an automatically generated action plan prioritizing your three lowest-scoring areas with specific next steps. Use it as a summary for board presentations, a strategic guide for your next governance cycle, or a collaborative diagnostic tool that aligns clinical, technical, compliance, and executive stakeholders around your current position and future directions.

Knowledge Base · Radiology Executives & IT Leadership

Radiology AI Data & Application Governance

A comprehensive interaction model for governing imaging data, AI models, and the people, policies, and platforms that connect them — from acquisition through retirement, across HIPAA, GDPR, FDA, and the EU AI Act.

Domains Covered 8 Governance Pillars

Lifecycle Stages 7 Data + 5 Model

Regulatory Frameworks HIPAA · GDPR · FDA · EU AI Act

Maturity Assessment 42 Items, 7 Domains

The Governance Imperative

AI in radiology is a data-intensive specialty where imaging archives hold rich identifiers, scanner metadata, and decades of clinical context. Responsible AI deployment demands governance that addresses algorithmic bias, transparency, and medico-legal accountability — not as a regulatory checkbox, but as a clinical safety discipline that runs in parallel with the technology itself.

Patient Privacy

PHI

Imaging metadata (device IDs, scan parameters, timestamps) can re-identify patients even after standard de-identification.

Data Quality

Multi-Site

Scanner, protocol, and population variation across sites is a primary source of bias and distributional shift.

Regulatory Surface

HIPAA, GDPR, FDA SaMD guidance, and the EU AI Act each impose distinct — and overlapping — obligations.

Liability Risk

Open

Liability for FDA-cleared AI tools that miss findings remains legally ambiguous between clinician, hospital, and vendor.

Scope of the Model

An AI data governance model in radiology spans imaging data from capture through disposal — primary clinical imaging (X-ray, CT, MRI, US, NM), derived annotations (radiologist reports, segmentations, structured findings), associated metadata, and the AI models trained on those data.

It governs both the data and the algorithms. Data without model oversight is incomplete; model oversight without data lineage is unverifiable.

Eight Governance Objectives

Protect patient privacy & security
Maintain data quality & integrity
Mitigate bias and ensure fairness
Achieve and document regulatory compliance
Establish accountability and transparency
Enable lawful innovation and research
Drive operational efficiency in AI adoption
Sustain trust with patients, clinicians, and regulators

What This Knowledge Base Delivers

For Radiology Executives

A defensible framework for board reporting, vendor diligence, and regulatory readiness — with maturity scoring that maps directly to investment priorities.

For IT Leadership

Technical control patterns (de-ID, federated learning, differential privacy, secure enclaves, audit trails) mapped to data lifecycle stages and risk tier.

For Compliance & Legal

A regulatory compass spanning HIPAA, GDPR, FDA SaMD, and the EU AI Act, with policy/SOP templates and DPIA checkpoints aligned to each authority.

Why Radiology Is Different

Unlike most health data, imaging data live in PACS with large file sizes, rich metadata, and indefinite retention horizons. They retain long-term scientific value — an MRI from 2015 may be the training datum for a 2027 model. That temporal asymmetry changes the privacy calculus, the consent calculus, and the data-stewardship calculus. Governance must treat de-identification as a process, not a one-time step, and treat retrospective imaging as a regulated asset class.

Stakeholders & the RACI Matrix

Successful AI governance is multidisciplinary. The most consistent lesson from leading academic medical centers and NHS trusts: stakeholder alignment, not technology, is the rate-limiting step. Below is a reference RACI matrix mapping core governance activities to the roles that should own them.

Core Governance Body

An AI Governance Steering Committee (or Radiology AI Working Group, depending on organizational scope) should convene at minimum the following voting roles:

Chief AI / Data & Analytics Officer (chair)
Radiology Clinical Lead (physician)
Lead Radiologic Technologist
Data Science / ML Lead
IT & Security Lead (CISO delegate)
Compliance & Privacy Officer
Legal Counsel
Patient / Community Liaison

Subcommittees

The steering committee typically delegates to standing subcommittees:

Technical Evaluation — model validation, drift review, retraining approvals
Ethics & Equity Review — bias audits, fairness metrics, patient impact
Vendor & Procurement — due diligence, BAAs/DPAs, contract terms
Incident Response — AI-related safety events, decommissioning

Penn Medicine and the NHS reported that explicit subcommittee structure was the single highest-leverage decision in their governance maturity.

RACI Matrix — Core Governance Activities

Activity	Radiologist	Data Sci.	IT / Security	Compliance	Exec / CDAO	Vendor	Patient Adv.
Define clinical use case & success criteria	R	C	I	I	A	I	C
Dataset curation & annotation QA	R	R	C	C	A	—	—
De-identification & PHI risk review	C	R	R	A	I	C	I
Model validation & clearance review	R	R	C	C	A	C	I
Bias & fairness audit	C	R	I	C	A	C	C
Drift monitoring & performance review	C	R	C	I	A	C	—
Vendor due diligence & contracting	C	C	R	R	A	C	—
Audit log review & access management	I	I	R	A	I	—	—
Incident response & decommissioning	R	R	R	C	A	C	I
Patient communication & transparency	C	I	I	R	A	—	R

R Responsible — performs the work A Accountable — answers for outcome C Consulted — expertise required I Informed — kept aware

Lessons from the Field

Penn Medicine

Convened a Radiology AI Committee with clinicians, AI experts, and administrators. Reported that the most important decision was “including all stakeholders in the process” and aligning department-level governance with enterprise-level AI priorities.

NHS Trust (Breast Imaging)

A consultant radiologist convened both an AI Working Group and an AI Project Group spanning clinicians, IT, legal, contracts, and R&D. Critical first step: setting an AI vision presented to executive leadership before any pilots launched.

The Imaging Data Lifecycle

Governance must address every stage of the data lifecycle — from the moment a scanner produces an image to the moment that image (or the model trained on it) is decommissioned. Each stage has distinct risks, controls, and accountable owners. Click any stage below to drill in.

Governance Checkpoints Across the Lifecycle

Each stage requires a defined approval gate before the data progresses. Suggested checkpoint mapping:

Pre-Acquisition Gate

Protocol standardization sign-off, scanner QA verification, consent framework documented in EHR/RIS workflow.

De-Identification Gate

Automated DICOM header scrub + burned-in-pixel detection + sample audit by privacy officer before any data leaves the clinical archive for AI use.

Access Gate

IRB or ethics review (research) or AI Committee approval (operational), Data Use Agreement on file, role-based access provisioned with time limits.

Sharing Gate

Re-identification risk assessment, HIPAA/GDPR pathway documented (limited dataset, anonymization, federated alternative), BAA/DPA executed.

Retention Gate

Annual review of dataset utility vs. retention obligations; archived datasets re-attested for ongoing research relevance.

Deletion Gate

Cryptographic erasure verification, model lineage updated to reflect dataset retirement, audit log permanently retained.

Technical Controls Library

Privacy-by-design in radiology AI rests on six interlocking technical controls. Each addresses a different failure mode — and each carries trade-offs that governance must explicitly accept.

Control 01

De-Identification & Anonymization

PHI Reduction DICOM

Removes or obfuscates direct identifiers (name, MRN, SSN) and indirect identifiers (device ID, scan parameters, acquisition timestamps, burned-in pixel annotations) from images and metadata. Standard tools include the RSNA Clinical Trial Processor (CTP), DICOM Toolkit, and commercial offerings.

Treat de-identification as a process, not a one-time transform. Audit a sample of every de-identified batch — burned-in pixels and free-text annotation fields are the most common leak vectors.

Trade-off: Aggressive scrubbing can strip clinically useful metadata (laterality, contrast phase). Build a metadata-retention whitelist with the radiology team, and apply Expert Determination (HIPAA) or Article 26 anonymization (GDPR) when re-identification risk must be formally certified.

Control 02

Federated Learning (FL)

Privacy-Preserving Multi-Site

Instead of pooling images centrally, each participating site trains a local copy of the model and shares only gradient updates with a central aggregator. Raw images never leave the originating institution. NVIDIA Clara FL, OpenFL, and TensorFlow Federated are the dominant frameworks for medical imaging.

FL is particularly valuable for rare-disease imaging, multi-center clinical trials, and any scenario where data localization laws (e.g., EU Member State-level restrictions) prohibit central pooling.

Trade-off: Gradient inversion attacks can leak training data from raw model updates. FL must be paired with differential privacy or secure aggregation to be defensible — FL alone is not a privacy guarantee.

Control 03

Differential Privacy (DP)

Formal Guarantee Utility Cost

Adds calibrated mathematical noise to data, gradients, or model outputs so that the contribution of any single patient cannot be recovered, providing a quantifiable privacy guarantee (the ε, δ budget). Commonly applied to FL gradient updates before aggregation.

Sensitivity-aware DP variants dynamically adjust noise magnitude based on the rarity or sensitivity of training samples, preserving more utility for common cases while protecting outliers.

Trade-off: Privacy is purchased with model accuracy. Governance must set an explicit, documented ε budget per use case — not let the data scientist tune it silently. High-stakes diagnostic models may not tolerate the noise level required for strong DP.

Control 04

Secure Computing Enclaves (TEE)

Hardware Isolation Emerging

Trusted Execution Environments (Intel SGX, AWS Nitro Enclaves, GCP Confidential VMs) compute on encrypted data inside hardware-isolated regions. Memory contents are invisible even to system administrators and cloud operators.

Useful pattern: a vendor’s algorithm runs inside the enclave on identifiable hospital data, and only aggregate inference results leave. The vendor never sees raw images; the hospital never exposes its data to vendor infrastructure.

Trade-off: Performance overhead and limited GPU enclave support today. Use selectively for the highest-risk workloads (un-de-identified images, external model validation), not as a default.

Control 05

Audit Trails & Provenance

HIPAA Required EU AI Act

Every action — data access, annotation, model training run, sharing event, inference query — generates an immutable audit record. This enables forensic review of breaches, regulatory inspection, and root-cause analysis of model failures.

Tooling: MLflow or Weights & Biases for model lineage; Splunk or ElasticSearch for system-level logs; data versioning via DVC or LakeFS. Integrate PACS access logs into the same audit fabric — siloed logs are unauditable in practice.

Trade-off: Comprehensive logging generates substantial volume. Define retention by log class (security events: 6+ years; performance telemetry: 1–2 years) and ensure logs themselves are protected from tampering.

Control 06

Encryption & Network Security

Foundational AES-256

Encryption at rest (AES-256) for PACS, archives, and AI training stores; TLS 1.3 for all in-flight data. Network segmentation isolates AI development environments from clinical production networks. Multi-factor authentication and role-based access control gate every system entry point.

For cloud AI workloads, customer-managed encryption keys (CMK) are the governance preference — cloud-provider-managed keys offer convenience but reduce institutional control over key rotation and revocation.

Trade-off: Key management is the operational hard part. A documented Key Management Policy with rotation cadence, escrow, and revocation procedures is non-negotiable.

Control Selection Decision Tree

Match controls to data sensitivity and use case — not all controls are warranted for all workloads.

Internal QI / Clinical Use

De-ID (where feasible) + audit trails + encryption + RBAC. Federated learning rarely needed.

Multi-Site Research

All foundational controls + FL with DP. Re-identification risk assessment required.

External Vendor Validation

All controls + secure enclave or zero-trust pattern. BAA/DPA mandatory; vendor must demonstrate equivalent posture.

Bias, Data Quality & Drift

High-quality, representative data is the foundation of trustworthy radiology AI. Bias is not a single problem but a class of failures — demographic, technical, geographic, label-quality, and temporal — each requiring different mitigation. Continuous drift monitoring closes the loop after deployment.

Five Sources of Bias in Imaging AI

Source 01 · Demographic

Skewed patient mix in training data

Datasets weighted toward one ethnicity, age band, sex, or body habitus produce models that systematically underperform on the underrepresented groups.

Source 02 · Equipment

Scanner & protocol variation

Different vendors, field strengths, reconstruction kernels, and acquisition protocols introduce distributional shifts that masquerade as “real” signal during training.

Source 03 · Geographic

Single-site training

A model trained at one academic center captures that institution’s case mix, referral patterns, and prevalence rates — not the world’s.

Source 04 · Label Quality

Annotator variability

Inter-reader disagreement, hurried free-text reports, and inconsistent grading scales propagate as label noise that the model learns as truth.

Source 05 · Spurious Correlation

Shortcut learning

Models latch onto image artifacts (chest tubes, laterality markers, hospital-specific image processing) instead of pathology — revealed only by explainability tools.

Mitigation Strategy Stack

Pre-Processing

Diversify & rebalance

Multi-site collaboration, oversampling underrepresented groups, augmentation, harmonization (e.g., ComBat for MRI). Document dataset demographics before training.

In-Processing

Fairness constraints

Add fairness regularization terms during training; adversarial debiasing; group-balanced loss functions. Frameworks: IBM AI Fairness 360, Aequitas.

Post-Processing

Output calibration

Calibrate threshold per subgroup to equalize false-positive or false-negative rates. Document the trade-off explicitly in the model card.

Auditing

Subgroup performance reporting

Mandatory subgroup metrics (sensitivity, specificity, AUC) by sex, age band, race/ethnicity (where ethically captured), scanner vendor, and site. Republish with each model update.

Explainability

XAI for bias discovery

Saliency maps, Grad-CAM, and counterfactual analysis surface which image features the model is actually using — the most reliable shortcut-learning detector.

Drift Monitoring

Continuous post-deployment

Track input distribution statistics and model confidence over time. Alerts on significant shifts trigger investigation, retraining, or temporary suspension.

Hypothetical Subgroup Performance Audit

Illustrative AUC by patient subgroup — gap of >0.05 between any two groups should trigger formal review.

Drift Signal Over 12 Months

Population stability index (PSI) on input feature distribution. PSI > 0.2 typically warrants investigation.

Drift Response Playbook

Detect. Automated PSI / KL-divergence / model confidence monitors alert on threshold crossing.

Investigate. Data science triages the alert: is it real drift, a data pipeline bug, or a population change? Root cause documented within 5 business days.

Decide. Governance committee chooses: continue monitoring, retrain on new data, restrict use to specific cohorts, or suspend the model.

Communicate. If clinical use is affected, end-users are notified the same day. Patient-impact analysis triggered if errors may have occurred.

Act. Retraining or decommissioning follows the model lifecycle SOP. Audit trail captures every step for regulatory inspection.

Model Lifecycle Governance

Governance for AI models parallels software quality management — but with clinical-safety stakes. Validation, explainability, monitoring, and version control all extend across a five-stage lifecycle that should be formalized in policy and enforced through MLOps tooling.

Develop

Use-case scoping, dataset curation, model design, documented training runs.

Validate

Internal & external test sets, subgroup performance, prospective silent pilot.

Deploy

Clinical integration, user training, rollout phasing, governance approval.

Monitor

Drift detection, performance audits, incident logging, user feedback loop.

Update / Retire

Retraining under change control, decommissioning SOP, lineage preservation.

Validation Tiers

Tier 1 — Internal Holdout

Model evaluated on held-out portion of training data. Reports AUC, sensitivity, specificity with confidence intervals. Necessary but insufficient.

Tier 2 — External Validation

Evaluation on data from sites and scanners not represented in training. Reveals geographic and equipment bias.

Tier 3 — Prospective Silent Pilot

Model runs in clinical environment without affecting care decisions; outputs compared to radiologist ground truth.

Tier 4 — Clinical Outcome Study

Live use with measured patient outcomes. Required for high-risk deployments under the EU AI Act.

Explainability Requirements

Models should produce interpretable outputs — saliency maps, attention weights, or feature attributions — that allow clinicians to understand and contest predictions. Governance should classify models by explainability tier:

High Glass-box model with native interpretability (rare in deep learning).

Medium Black-box model paired with post-hoc XAI (Grad-CAM, SHAP, LIME).

Low Black-box with no XAI — should be flagged as elevated risk and require additional human-in-the-loop controls.

Opacity in image-based AI is a documented patient-safety concern and should never be accepted silently.

Predetermined Change Control Plan (PCCP)

The FDA’s evolving guidance for AI/ML-enabled SaMD permits pre-authorized model modifications under a Predetermined Change Control Plan. Governance should mirror this internally even when not legally required: define before deployment what classes of update are pre-approved, what require re-review, and what trigger a new clearance.

Pre-Approved Updates

Retraining on additional data of the same type and population, with no architecture change. Approved by AI Committee chair.

Standard Re-Review

Architecture changes, new input modalities, expanded indications. Full Technical Evaluation Subcommittee review.

Major Re-Clearance

New clinical claims, new patient populations, change in intended use. Full governance review and, if SaMD, FDA notification.

CI/CD for Clinical AI

Continuous Integration / Continuous Deployment pipelines should automate the mechanical work of retraining and testing — but never bypass human review for clinical models. A defensible pipeline includes:

Automated dataset versioning with cryptographic hashes (DVC, LakeFS)
Automated training-run logging (MLflow, Weights & Biases) with hyperparameters and metrics
Automated unit tests, integration tests, and regression tests on held-out gold sets
Automated subgroup performance evaluation with fairness gates
Mandatory human approval gate before any deployment to production inference
Automated rollback capability if monitoring detects post-deployment regression

Decommissioning — The Forgotten Stage

Most AI governance frameworks address deployment exhaustively and decommissioning sparsely. A model that is no longer monitored, no longer maintained, or no longer aligned to current data has become a latent risk. Governance must define:

Clear triggers for decommissioning (sustained drift, vendor exit, superseded by replacement, policy change)
Communication plan for end-users and downstream systems
Archival of model artifacts, training data lineage, and validation history (regulatory inspection may follow years later)
Post-mortem review documenting lessons learned for future deployments

The Regulatory Compass

Radiology AI sits at the intersection of privacy law, medical device law, and emerging AI-specific law. Each authority imposes overlapping obligations — treating them as one program with one mapping is more efficient than running parallel compliance tracks.

USA

HIPAA

Privacy & Security Rules — PHI protection

Technical safeguards: access control, audit logs, encryption
De-identification via Safe Harbor or Expert Determination
Business Associate Agreements with all vendors
6-year retention of audit logs & policies
Breach notification within 60 days
Limited Data Sets permitted with DUA for research

GDPR

General Data Protection Regulation

Lawful basis required for every processing activity
Data Protection Impact Assessment (DPIA) for AI uses
Patient rights: access, rectification, erasure, portability
Privacy by design and by default mandated
Pseudonymized data still personal data; only true anonymization escapes scope
Data Processing Agreements with all processors

USA

FDA SaMD

Software as a Medical Device guidance

Premarket review: 510(k), De Novo, or PMA pathway
Good Machine Learning Practice (GMLP) principles
Predetermined Change Control Plan for updates
Quality Management System (ISO 13485 alignment)
Real-world performance monitoring expectations
Transparency & algorithm change communication

EU AI Act

High-risk AI obligations (clinical AI ≡ high-risk)

Risk management system across the AI lifecycle
Data governance: relevance, representativeness, error analysis
Technical documentation & record-keeping
Transparency to users (clear AI disclosure)
Human oversight mandatory
Accuracy, robustness, and cybersecurity requirements
Post-market monitoring & serious incident reporting

MDR / IVDR

Medical Device & In Vitro Diagnostic Regulations

CE marking via Notified Body (most clinical AI is Class IIa+)
Clinical evaluation and Post-Market Clinical Follow-up
Unique Device Identification (UDI)
EUDAMED registration
Risk management per ISO 14971

Global

ISO / IEC Standards

Voluntary frameworks adopted as de facto requirements

ISO/IEC 27001 — Information security management
ISO/IEC 23894 — AI risk management guidance
ISO/IEC 42001 — AI management system
ISO 13485 — Medical device QMS
ISO 14971 — Medical device risk management

USA

NIST AI RMF

Voluntary AI Risk Management Framework

Govern — culture, policies, accountability
Map — context, use case, risk identification
Measure — quantitative & qualitative analysis
Manage — prioritize, respond, communicate, monitor
Increasingly cited in federal procurement & state laws

Global

Professional Society Guidance

ACR, RANZCR, RSNA, ESR ethics & practice

Stakeholder consultation expectations
Professional accountability frameworks
Model card / dataset card disclosure norms
Continuing education requirements for AI use

One Program, Many Authorities — A Unified Mapping

Rather than running separate HIPAA, GDPR, FDA, and EU AI Act compliance tracks, map your governance controls once to all relevant authorities. Each requirement an authority imposes typically overlaps with two or three others. The pattern that scales:

Authority × Control Crosswalk

Build a matrix where rows are your governance controls and columns are the authorities. A single audit log requirement, for example, satisfies HIPAA, GDPR Article 30, EU AI Act Article 12, and ISO 27001 simultaneously — documented once.

Single Source of Truth

Maintain one policy library, one risk register, one DPIA template, and one model card template. Tag each document with the authorities it satisfies. This dramatically simplifies audits and inspections.

Governance Maturity Assessment

Rate your organization on each of 42 items across 7 governance domains. Scores generate an overall maturity level, a radar of domain strength, and a prioritized action plan focused on the lowest-scoring areas.

Overall Maturity

—

Begin assessment to see your score

5-point scale · 1=Initial · 5=Optimized

Auto-Generated Action Plan

Recommendations are prioritized by lowest-scoring domains first. Complete the assessment above to populate this section.

Action plan will appear after you rate at least one domain…

Maturity Bands

1.0–1.9 · Initial

Ad-hoc, undocumented, person-dependent.

2.0–2.9 · Developing

Some policies exist, inconsistently applied.

3.0–3.5 · Defined

Documented, trained, applied across most projects.

3.6–4.4 · Managed

Measured, monitored, continuously improved.

4.5–5.0 · Optimized

Embedded in culture, externally auditable, drives strategy.